EUCTR2014-003656-31-GB进行中（未招募）1 期
Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers - ABC-07
niversity College London0 个研究点目标入组 81 人开始时间: 2015年6月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. A histopathological/cytological diagnosis of locally advanced, non-resectable biliary tract carcinoma (intra- or extra-hepatic), (excluding cancer of the gall bladder and ampullary carcinoma)
- •2. Not suitable for radical surgery, or medically unfit for surgery as decided by a hepatobiliary MDT
- •3. Tumour visible on cross-sectional imaging
- •4. Measurable disease (according to RECIST criteria v1.1). (If disease is not measurable using RECIST v1.1, the tumour must be visible for targeting with radiation).
- •5. Tumour (and nodes if involved) must be =12 cm in the longest dimension. For patients with non-measurable disease, sites should use the CT reconstructions (coronal or sagittal views) to measure tumour size.
- •6. Adequate biliary drainage
- •7. WHO PS 0 or 1
- •8. Adequate haematological function:
- •Haemoglobin = 100 g/L (the use of transfusion to achieve desired Hb is acceptable)
- •White blood cell count (WBC) = 3.0 x 109/L
- •Absolute neutrophil count (ANC) =1.5 x 109/L
- •Platelet count = 100 x 109/L
- •9. Adequate liver function:
- •Total bilirubin =3.0 x ULN. Total bilirubin levels must be considered stable by the treating clinician e.g. more than one reading is required to show they are stable. Exceptions are possible for patients with known documented cases of Gilbert’s syndrome, as long as the Bilirubin is stable and the treating clinician feels that the increased bilirubin is not due to obstruction or cholangitis.
- •ALT and/or AST = 2.5 x ULN
- •ALP = 5 x ULN
- •Albumin > 25 g/L
- •10. Adequate renal function:
- •Serum urea < 1.5 x ULN
- •Serum creatinine < 1.5 x ULN
- •GFR = 45 mL/min using a validated creatinine clearance calculation (e.g. Cockroft-Gault or Wright formula). If the calculated creatinine clearance is less than 45 mL/min, GFR should be assessed using an isotopic clearance method to confirm GFR = 45 mL/min. Alternatively, if calculated GFR is <45mL/min, a protein/creatinine ratio can be used in 24 hours collected urine to confirm GFR = 45 mL/min .
- •11. Life expectancy >12 weeks
- •12. 16 years of age or over
- •13. Patients may have had prior chemotherapy as long as patient meets all other inclusion/exclusion criteria.
- •14. Patient must have given written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. Metastatic disease
- •2. Direct tumour extension in the duodenum, stomach, small bowel or large bowel.
- •3. Previous abdominal radiotherapy or previous selective internal radiotherapy such as hepatic arterial Yttrium therapy
- •4. Previous hypersensitivity to platinum salts
- •5. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial (including diabetes with established sensory peripheral neuropathy, unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
- •5.Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial (including diabetes with established sensory peripheral neuropathy, unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
- •6.Patients who have a concurrent malignancy that is clinically unstable and requires tumour-directed treatment are not eligible. Exceptions include low grade malignancies that do not require active treatment, such as early prostate cancer under surveillance or chronic lymphocytic leukaemia.
- •7. History of prior malignancy that could interfere with the response evaluation or survival. Exceptions include:
- •in-situ carcinoma of the cervix treated by cone-biopsy/resection,
- •non-metastatic basal and/or squamous cell carcinomas of the skin,
- •any early stage malignancy diagnosed over two years ago and radically treated.
- •8. Other concomitant anti-cancer therapy (except steroids)
- •9. Any psychiatric or other disorder likely to impact on informed consent.
- •10. Women who are pregnant or breast feeding
- •NB. Whilst not excluded, patients with significant hearing impairment must be made aware of potential ototoxicity and may choose not to be included. If included, it is recommended that audiograms be carried out at baseline and prior cycle 2 of CisGem
研究者
相似试验
进行中（未招募）
不适用
A trial looking at whether stereotactic radiotherapy together with chemotherapy is a useful treatment for people with locally advanced bile duct cancer (ABC-07)Biliary tract cancerMalignant neoplasm of other and unspecified parts of biliary tractCancerISRCTN10639376niversity College London83
已完成
2 期
Addition of stereotactic radiotherapy to the standard FOLFIRINOX treatment in locally advanced pancreatic cancer patients to determine efficacy and feasability (LAPC-1)locally advanced pancreatic carcinoma1001567410017991Pancreatic cancerNL-OMON44466Stichting Leveronderzoek51
Unknown
不适用
Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.locally advanced pancreatic cancerpancreatic neoplasmFOLFIRINOXstereotactic radiotherapyNL-OMON27030Foundation for Liver and Gastrointestinal Research51
招募中
不适用
Potential abscopal effect of stereotactic body radiotherapy on the recurrence of hepatocellular carcinoma: An exploratory observation studyHepatocellular carcinomaJPRN-UMIN000038312ational Hospital Organization Nagasaki Medical Center280
招募中
不适用
Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local RecurrencesC61Malignant neoplasm of prostateDRKS00030837Europäisches Radiochirurgie Centrum München50